Fibromyalgia Syndrome - A Pipeline Analysis Report

Overview of the drug development pipeline for fibromyalgia syndrome

It has been observed that primary fibromyalgia syndrome is one of the most common chronic pain conditions and is characterized by stiff joints and muscles in the morning, difficulties with memory and concentration, and irregular sleep patterns. Primary fibromyalgia syndrome causes widespread pain, fatigue, and other types of discomfort. Symptoms of fibromyalgia syndrome can appear at any time during a person’s life, but they are most commonly reported around the age of 45 years.

Fibromyalgia can also be hereditary. Females who have a close relative with primary fibromyalgia syndrome are at a higher risk of developing this syndrome. Also, people suffering from rheumatoid arthritis, lupus, or spinal arthritis have a high risk of developing primary fibromyalgia syndrome. According to an article published by National Institute of Health (NIH) under Creative Public Domain, fibromyalgia syndrome was identified in 1.75% (3.94 million) persons from a sample of 225.7 million. The most efficient approach for the treatment of fibromyalgia syndrome is considered to be monotherapy.

According to this pipeline analysis report, all the drug molecules in the pipeline are being developed for primary fibromyalgia syndrome. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

Want a bigger picture? Try a FREE sample of this report now!

Pipeline analysis report on drug development for fibromyalgia syndrome: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of fibromyalgia syndrome. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are

• Abide Therapeutics
• Aptinyx
• Astellas Pharma
• DAIICHI SANKYO COMPANY
• Immune Therapeutics

Therapeutic assessment of the drug development pipeline for fibromyalgia syndrome by route of administration

• Oral
• Nasal
• Transdermal
• Unknown

The oral route of administration (ROA) involves the application of the drug directly into the mouth cavity, which will have a more direct effect on the target cells and in the nasal technique, the molecules are delivered through the nasal cavity. The transdermal ROA involves delivery of the drug molecules in the form of absorption through the skin into the bloodstream

Therapeutic assessment of the drug development pipeline for fibromyalgia syndrome by therapy

• Monotherapy
• Combination therapy

According to this pipeline analysis report, most of the molecules that are currently in the drug development pipeline for fibromyalgia syndrome are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.

Key questions answered in the report include

• What are the drug molecules in the various development stages for fibromyalgia syndrome?
• What are the companies that are currently involved in the development of drug molecules for fibromyalgia syndrome?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.